Equillium Company Insiders
| EQ Stock | USD 1.71 0.10 5.52% |
Equillium's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Equillium suggests that virtually all insiders are panicking. Equillium employs about 44 people. The company is managed by 24 executives with a total tenure of roughly 143 years, averaging almost 5.0 years of service per executive, having 1.83 employees per reported executive.
| Geoffrey Rotstein CEO President CEO, Director |
| Daniel Bradbury Chairman Chairman of the Board, CEO |
Equillium's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2022-08-29 | Jason A Keyes | Disposed 7000 @ 2.83 | View | ||
| 2022-06-06 | Jason A Keyes | Disposed 5000 @ 2.52 | View | ||
| 2022-04-04 | Jason A Keyes | Disposed 8000 @ 3.18 | View | ||
| 2021-12-01 | Jason A Keyes | Disposed 5000 @ 5.08 | View | ||
| 2021-10-06 | Stephen Connelly | Disposed 8092 @ 7.01 | View | ||
| 2021-09-27 | Jason A Keyes | Disposed 8000 @ 6.74 | View | ||
| 2021-07-27 | Jason A. Keyes | Disposed 5000 @ 5.72 | View | ||
| 2021-06-08 | Stephen Connelly | Disposed 10495 @ 7.18 | View | ||
| 2021-06-04 | Stephen Connelly | Disposed 13539 @ 7.01 | View | ||
| 2021-05-26 | Jason A Keyes | Disposed 5000 @ 6.5 | View |
Monitoring Equillium's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Equillium |
Equillium Management Team Effectiveness
The company has Return on Asset (ROA) of (0.1408) % which means that for every 100 dollars spent on asset, it generated a loss of $0.1408. This is way below average. Likewise, it shows a return on total equity (ROE) of (0.4892) %, which implies that it produced no returns to current stockholders. Equillium's management efficiency ratios could be used to measure how well Equillium manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/26/2024, Return On Tangible Assets is likely to drop to -0.28. In addition to that, Return On Capital Employed is likely to drop to -0.66. At this time, Equillium's Total Current Liabilities is relatively stable compared to the past year. As of 04/26/2024, Liabilities And Stockholders Equity is likely to grow to about 67.5 M, while Non Current Liabilities Total is likely to drop slightly above 364.8 K.As of 04/26/2024, Common Stock Shares Outstanding is likely to drop to about 25.8 M. In addition to that, Net Loss is likely to grow to about (53.4 M)
Equillium Workforce Comparison
Equillium is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 1,779. Equillium holds roughly 44.0 in number of employees claiming about 2.47% of equities under Health Care industry.
Equillium Profit Margins
The company has Net Profit Margin (PM) of (0.37) %, which may indicate that it does not properly execute on its own pricing strategies. This is way below average. Likewise, it shows Net Operating Margin (NOM) of (0.35) %, which signifies that for every 100 dollars of sales, it has a net operating loss of $0.35.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.79 | 0.9965 |
|
|
Equillium Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Equillium insiders, such as employees or executives, is commonly permitted as long as it does not rely on Equillium's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Equillium insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Stephen Connelly 3 days ago Disposition of 8490 shares by Stephen Connelly of Equillium at 7.0842 subject to Rule 16b-3 | ||
Zedelmayer Christine over a week ago Acquisition by Zedelmayer Christine of 8334 shares of Equillium at 2.45 subject to Rule 16b-3 | ||
Joel Rothman over a month ago Acquisition by Joel Rothman of 8804 shares of Equillium subject to Rule 16b-3 | ||
Jason Keyes over three months ago Acquisition by Jason Keyes of 15000 shares of Equillium subject to Rule 16b-3 | ||
Charles McDermott over six months ago Acquisition by Charles McDermott of 24000 shares of Equillium subject to Rule 16b-3 |
Equillium Notable Stakeholders
An Equillium stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Equillium often face trade-offs trying to please all of them. Equillium's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Equillium's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Geoffrey Rotstein | President CEO, Director | Profile | |
| Daniel Bradbury | Chairman of the Board, CEO | Profile | |
| Vernon Lobo | Independent Chairman of the Board | Profile | |
| Bruce Steel | President Chief Business Officer and Director | Profile | |
| Bruce CFA | President, CoFounder | Profile | |
| Peter Kanniah | CFO, Secretary | Profile | |
| PMP MBA | Senior COO | Profile | |
| Dilshan Kathriarachchi | CTO | Profile | |
| John Fisher | Independent Director | Profile | |
| Anthony Tjan | Independent Director | Profile | |
| Marc Lavine | Independent Director | Profile | |
| Charles McDermott | Independent Director | Profile | |
| Bala Manian | Independent Director | Profile | |
| Stephen Connelly | Chief Scientific Officer, Director | Profile | |
| Martha Demski | Independent Director | Profile | |
| Mark Pruzanski | Independent Director | Profile | |
| Jason Keyes | Chief Officer | Profile | |
| Penny Tom | Principal Officer | Profile | |
| Joel Rothman | Chief Officer | Profile | |
| Krishna Polu | Chief Medical Officer | Profile | |
| Matthew Ritter | Senior Development | Profile | |
| Maple MD | Chief Officer | Profile | |
| Krishna MD | Consultant | Profile | |
| Michael Moore | Vice Communications | Profile |
About Equillium Management Performance
The success or failure of an entity such as Equillium often depends on how effective the management is. Equillium management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Equillium management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Equillium management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.26) | (0.28) | |
| Return On Capital Employed | (0.63) | (0.66) | |
| Return On Assets | (0.26) | (0.28) | |
| Return On Equity | (0.59) | (0.62) |
The data published in Equillium's official financial statements usually reflect Equillium's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Equillium. For example, before you start analyzing numbers published by Equillium accountants, it's critical to develop an understanding of what Equillium's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Equillium's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Equillium's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Equillium's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Equillium. Please utilize our Beneish M Score to check the likelihood of Equillium's management manipulating its earnings.
Equillium Workforce Analysis
Traditionally, organizations such as Equillium use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Equillium within its industry.Equillium Manpower Efficiency
Return on Equillium Manpower
| Revenue Per Employee | 820.1K | |
| Revenue Per Executive | 1.5M | |
| Net Loss Per Employee | 303.1K | |
| Net Loss Per Executive | 555.6K | |
| Working Capital Per Employee | 494.9K | |
| Working Capital Per Executive | 907.3K |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Equillium. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index. To learn how to invest in Equillium Stock, please use our How to Invest in Equillium guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Equillium Stock analysis
When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Equillium's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Equillium. If investors know Equillium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Equillium listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.38) | Revenue Per Share 1.039 | Quarterly Revenue Growth (0.42) | Return On Assets (0.14) | Return On Equity (0.49) |
The market value of Equillium is measured differently than its book value, which is the value of Equillium that is recorded on the company's balance sheet. Investors also form their own opinion of Equillium's value that differs from its market value or its book value, called intrinsic value, which is Equillium's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Equillium's market value can be influenced by many factors that don't directly affect Equillium's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Equillium's value and its price as these two are different measures arrived at by different means. Investors typically determine if Equillium is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Equillium's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.